ELEV Elevation Oncology, Inc.

Nasdaq elevationoncology.com


$ 0.38 $ -0.01 (-2.12 %)    

Tuesday, 22-Jul-2025 18:28:32 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 0.365
$ 0.37
$ 0.00 x 0
$ 0.00 x 0
-- - --
$ 0.22 - $ 3.09
4,819,177
na
21.62M
$ 169.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2025 03-31-2025 10-Q
2 03-06-2025 01-01-1970 10-K
3 11-06-2024 09-30-2024 10-Q
4 08-06-2024 06-30-2024 10-Q
5 05-02-2024 03-31-2024 10-Q
6 03-06-2024 12-31-2023 10-K
7 11-02-2023 09-30-2023 10-Q
8 08-03-2023 06-30-2023 10-Q
9 05-15-2023 03-31-2023 10-Q
10 03-09-2023 12-31-2022 10-K
11 11-03-2022 09-30-2022 10-Q
12 08-04-2022 06-30-2022 10-Q
13 05-05-2022 03-31-2022 10-Q
14 03-03-2022 12-31-2021 10-K
15 11-12-2021 09-30-2021 10-Q
16 08-12-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://www.wsj.com/health/healthcare/medicare-part-d-drug-plan-premiums-set-to-rise-16ef919c

 elevation-oncology-license-agreement-with-cspc-megalith-biopharmaceutical-terminated-as-of-june-26-2025-termination-agreement-includes-mutual-release-of-claims

-SEC Filing

Core News & Articles

https://www.wsj.com/politics/policy/lawmakers-seek-to-close-va-loophole-that-funnels-billions-to-private-medicare-insurers-cfbe...

Core News & Articles

https://www.bloomberg.com/news/articles/2025-06-16/senate-republicans-to-omit-medicare-advantage-cuts-in-tax-bill?embedded-chec...

 jmp-securities-reiterates-market-perform-on-elevation-oncologyto-market-perform

JMP Securities analyst Silvan Tuerkcan reiterates Elevation Oncology (NASDAQ:ELEV) from Market Perform to Market Perform.

 hc-wainwright--co-downgrades-elevation-oncology-to-neutral-lowers-price-target-to-036

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Elevation Oncology (NASDAQ:ELEV) from Buy to Neutral and l...

 william-blair-downgrades-elevation-oncology-to-market-perform

William Blair analyst Andy Hsieh downgrades Elevation Oncology (NASDAQ:ELEV) from Outperform to Market Perform.

 concentra-biosciences-to-acquire-elevation-oncology-for-036-in-cash-per-share-of-elevation-oncology-common-stock-plus-one-non-tradeable-contingent-value-right

Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective ca...

Core News & Articles

https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-poli...

Core News & Articles

https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-poli...

Core News & Articles

CMS Rolls Out Aggressive Strategy to Enhance and Accelerate Medicare Advantage Audits

 elevation-oncology-to-present-data-for-eo-1022-at-american-association-for-cancer-research-annual-meeting-2025

-- Abstract accepted for late-breaking poster presentation –-- EO-1022 is a potentially differentiated HER3 ADC being developed...

 stephens--co-downgrades-elevation-oncology-to-equal-weight-lowers-price-target-to-1

Stephens & Co. analyst Sudan Loganathan downgrades Elevation Oncology (NASDAQ:ELEV) from Overweight to Equal-Weight and ...

 piper-sandler-downgrades-elevation-oncology-to-neutral-lowers-price-target-to-07

Piper Sandler analyst Biren Amin downgrades Elevation Oncology (NASDAQ:ELEV) from Overweight to Neutral and lowers the price...

 citizens-capital-markets-downgrades-elevation-oncology-to-market-perform-maintains-price-target-to-7

Citizens Capital Markets analyst Silvan Tuerkcan downgrades Elevation Oncology (NASDAQ:ELEV) from Market Outperform to Marke...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION